Well put 4kids. I too do my best to keep emotion out of
Well put 4kids. I too do my best to keep emotion out of it. Otherwise I would have moved on long ago. The science potential is why I'm still here. Simply being on the OTC makes any stock a sitting duck for abuse and to me, it seems, the greatest of them are also the ones facing the most attacks against them. Almost like the number of attackers is commensurate with the potential reward once the science is proven.
Leo knows this game. And if $IPIX succeeds, I hope they hunt all of those turkeys down.
As far as setting expectations, there are fundamental expectations that should be constant in any company. Filing on time is one of them. And of course following through with their own stated goals. Unfortunately that's the knife that helped put us where we are today. And the way to counter that is again the same thing. Follow through. And yes, the trolls use anything and everything they can to post their reminders of any little thing they can find. My timeline "12 - 18" days is just a guestamate.
The path they're on right now planning the US and EU trial for brilacidin is an excellent plan. And I do believe we'll see the follow through.
1
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Soaring Net Income and Impressive Growth Franklin Financial Services Corporation (NASDAQ: FRAF) seems to be on a roll this year, painting a vivid picture of growth as they close out the third quarter of 2026. With a strong surge in net income—59.4% up from Q3 2025—this leadership in earnings is no fluke. Net Income and Earnings per Share Let's break it down: the...
Continue Reading
A Bold African Initiative Alright, folks, let's get into the nitty-gritty of Sinopec's game plan in Africa. There's something to be said about a behemoth like Sinopec rolling out a sustainability report with real substance. We're looking at 33 projects across 16 countries, $5.7 billion in investments. Now, that's not just pocket change. Economic Muscle and Environmental...
Continue Reading
Skyrocketing Demand in Medical Device Manufacturing You're looking at a market that's gearing up to hit a whopping $135.47 billion by 2031. That's a big leap from its $85.59 billion stature in 2026, showing a strong 9.6% compound annual growth rate (CAGR). Now, if that doesn't get your investor rollercoaster senses tingling, I don't know what will. Key Growth Drivers The...
Continue Reading
Jiahui's International Cell Therapy Center: A New Era Jiahui International Hospital is shaking up the healthcare scene with its fresh International Cell Therapy Center, diving headfirst into the cutting-edge world of CAR-T treatments. It's not every day you see this kind of bold move, especially from a player aiming to extend their reach both in China and abroad. Let's...
Continue Reading
Etisalat's Stellar Performance: A Deeper Dive When a company like Etisalat drops news of a whopping 46% increase in net profit year-over-year, you sit up and pay attention. Those numbers aren’t just a flash in the pan; they're the result of some serious strategic maneuvers and ripe market conditions. Etisalat isn't resting on its laurels, and their latest financials...
Continue Reading
Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...
Continue Reading
The Bladder Cancer Scene: Steady as She Goes Sometimes, you look at numbers and find tranquility, like staring into still waters. That's the scene over at Photocure ASA with their latest Q3 results. Clocking in with revenues of NOK 134.2 million from their Hexvix®/Cysview® products, they're barely flinching from last year's NOK 134.1 million. Is it a victory or a...
Continue Reading
A Closer Look at Bank Leumi's Upcoming Q3 Release Take a seat, folks. Bank Leumi’s gearing up to spill the beans on their Third Quarter 2026 earnings come November 17th. If you’re in the financial world, you might want to mark your calendar because these reports tend to shake things up. You know how these go - numbers rolling out, market responses, and plenty of...
Continue Reading
An Eye on the Future: oToBrite's Bold Vision for Robotics Strolling down the aisles at ROBOTWORLD 2026, there's a palpable energy buzzing around oToBrite's booth. These folks are showcasing vision technology that's not just about snapping slick photos—it's about reshaping how machines see the world. And, let me tell you, if there’s one place to flaunt cutting-edge...
Continue Reading
Payout Boost for Income-Hungry Investors You know, it ain't every day you hear about dividend increases across the board. But Infrastructure Capital Advisors, that investment management powerhouse, is dishing out more dough to its investors through a dividend uptick. They're bumping up the payouts on not just one, but four of their ETFs: Bond Income ETF (BNDS), Equity...
Continue Reading
Top 5 Most Recently Viewed Articles
Strong Sales Growth in Q3 for SMCP The latest sales report for SMCP has highlighted a solid growth trajectory in the third quarter. The performance is attributed to robust activities in the America and EMEA regions, showcasing the effectiveness of the company's strategic initiatives. Sales Overview and Highlights In the first nine months of 2025, SMCP achieved impressive...
Continue Reading
InflaRx to Participate in Major Investor Conferences In a noteworthy announcement, InflaRx N.V. (Nasdaq: IFRX), a leading biopharmaceutical company specializing in anti-inflammatory therapeutics, is gearing up for participation in two significant investor conferences in September. This engagement comes as the company continues to push boundaries in treating inflammatory...
Continue Reading
Rapid7 to Attend Prominent Conference Rapid7, Inc. (NASDAQ:RPD), a frontrunner in threat detection and exposure management, has recently announced its participation in a significant event: the Raymond James TMT and Consumer Conference. This notable conference will take place in New York, providing a platform where industry leaders gather to discuss innovations and...
Continue Reading
Theriva Biologics Expands Opportunities with New Offering Theriva Biologics (NYSE American: TOVX), a clinical-stage company focused on developing innovative cancer therapeutics, has recently completed a significant public offering aimed at raising $7.5 million. This initiative is not only a financial step for Theriva but also a strategic move to enhance its research...
Continue Reading
Costco's New Board Nominee Costco Wholesale Corporation (NASDAQ: COST) has announced the nomination of Gina Raimondo to its Board of Directors. Raimondo, who has an impressive track record, served as the 40th Secretary of Commerce and held the position of Governor of Rhode Island. Her political career began in 2010 when she was elected as the Treasurer of Rhode Island....
Continue Reading